(0.28%) 5 146.00 points
(0.30%) 38 557 points
(0.37%) 17 913 points
(-0.85%) $83.14
(1.25%) $1.947
(-0.15%) $2 343.60
(0.20%) $27.59
(0.85%) $929.90
(-0.29%) $0.932
(-0.38%) $10.98
(-0.38%) $0.797
(0.25%) $92.11
Live Chart Being Loaded With Signals
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes...
Stats | |
---|---|
本日の出来高 | 13.77M |
平均出来高 | 7.44M |
時価総額 | 5.26B |
EPS | £0 ( 2024-03-05 ) |
Last Dividend | £1.380 ( 2023-08-17 ) |
Next Dividend | £0 ( N/A ) |
P/E | 51.56 |
ATR14 | £0.438 (0.17%) |
ボリューム 相関
ConvaTec Group PLC 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ConvaTec Group PLC 相関 - 通貨/商品
ConvaTec Group PLC 財務諸表
Annual | 2023 |
収益: | £2.14B |
総利益: | £1.20B (56.04 %) |
EPS: | £0.0640 |
FY | 2023 |
収益: | £2.14B |
総利益: | £1.20B (56.04 %) |
EPS: | £0.0640 |
FY | 2022 |
収益: | £2.07B |
総利益: | £1.12B (53.92 %) |
EPS: | £0.0311 |
FY | 2021 |
収益: | £2.04B |
総利益: | £1.12B (55.10 %) |
EPS: | £0.0590 |
Financial Reports:
No articles found.
ConvaTec Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£1.410 (N/A) |
£0 (N/A) |
£0 (N/A) |
£3.66 (N/A) |
£1.380 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.061 | 2017-09-07 |
Last Dividend | £1.380 | 2023-08-17 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | £28.05 | -- |
Avg. Dividend % Per Year | 1.46% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 8.79 | |
Div.Growth Potential Score | 3.50 | |
Div. Directional Score | 6.14 | -- |
Year | Amount | Yield |
---|---|---|
2017 | £0 | 0.00% |
2018 | £4.40 | 2.05% |
2019 | £4.50 | 3.31% |
2020 | £4.40 | 2.23% |
2021 | £4.08 | 1.99% |
2022 | £4.57 | 2.36% |
2023 | £5.04 | 2.16% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SEQI.L | Dividend Knight | 2023-07-27 | Quarterly | 10 | 3.85% | |
ICGC.L | Dividend Knight | 2023-09-14 | Annually | 15 | 1.80% | |
BISI.L | Dividend Knight | 2024-01-04 | Annually | 32 | 2.05% | |
WTB.L | Dividend Knight | 2023-05-25 | Annually | 33 | 0.87% | |
NTV.L | Dividend Knight | 2023-07-20 | Semi-Annually | 25 | 4.03% | |
EMG.L | Dividend King | 2023-08-10 | Semi-Annually | 31 | 3.60% | |
SPT.L | Dividend Knight | 2023-08-10 | Semi-Annually | 32 | 1.51% | |
JD.L | Dividend Knight | 2023-12-07 | Annually | 28 | 0.21% | |
BUT.L | Dividend King | 2023-08-03 | Quarterly | 49 | 1.28% | |
PNL.L | Dividend Knight | 2023-08-24 | Quarterly | 41 | 0.75% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0608 | 1.500 | 8.78 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0351 | 1.200 | 8.83 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0785 | 1.500 | -0.239 | -0.358 | [0.1 - 1] |
payoutRatioTTM | 0.850 | -1.000 | 1.504 | -1.504 | [0 - 1] |
currentRatioTTM | 1.622 | 0.800 | 6.89 | 5.51 | [1 - 3] |
quickRatioTTM | 0.686 | 0.800 | -0.669 | -0.535 | [0.8 - 2.5] |
cashRatioTTM | 0.182 | 1.500 | -0.100 | -0.150 | [0.2 - 2] |
debtRatioTTM | 0.353 | -1.500 | 4.11 | -6.17 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.177 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.115 | 2.00 | 9.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.775 | -1.500 | 6.90 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.562 | 1.000 | 3.97 | 3.97 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.131 | 1.000 | 9.39 | 9.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.280 | 1.000 | 9.56 | 9.56 | [0.2 - 2] |
assetTurnoverTTM | 0.577 | 0.800 | 9.49 | 7.59 | [0.5 - 2] |
Total Score | 8.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 51.24 | 1.000 | 4.93 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0785 | 2.50 | -0.153 | -0.358 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.115 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.520 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.177 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.850 | 1.500 | 1.504 | -1.504 | [0 - 1] |
pegRatioTTM | -63.57 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.171 | 1.000 | 8.21 | 0 | [0.1 - 0.5] |
Total Score | 3.50 |
ConvaTec Group PLC
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。